Cargando…

Targeted Intracellular Delivery of Antibodies: The State of the Art

A dominant area of antibody research is the extension of the use of this mighty experimental and therapeutic tool for the specific detection of molecules for diagnostics, visualization, and activity blocking. Despite the ability to raise antibodies against different proteins, numerous applications o...

Descripción completa

Detalles Bibliográficos
Autores principales: Slastnikova, Tatiana A., Ulasov, A. V., Rosenkranz, A. A., Sobolev, A. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207587/
https://www.ncbi.nlm.nih.gov/pubmed/30405420
http://dx.doi.org/10.3389/fphar.2018.01208
_version_ 1783366537456910336
author Slastnikova, Tatiana A.
Ulasov, A. V.
Rosenkranz, A. A.
Sobolev, A. S.
author_facet Slastnikova, Tatiana A.
Ulasov, A. V.
Rosenkranz, A. A.
Sobolev, A. S.
author_sort Slastnikova, Tatiana A.
collection PubMed
description A dominant area of antibody research is the extension of the use of this mighty experimental and therapeutic tool for the specific detection of molecules for diagnostics, visualization, and activity blocking. Despite the ability to raise antibodies against different proteins, numerous applications of antibodies in basic research fields, clinical practice, and biotechnology are restricted to permeabilized cells or extracellular antigens, such as membrane or secreted proteins. With the exception of small groups of autoantibodies, natural antibodies to intracellular targets cannot be used within living cells. This excludes the scope of a major class of intracellular targets, including some infamous cancer-associated molecules. Some of these targets are still not druggable via small molecules because of large flat contact areas and the absence of deep hydrophobic pockets in which small molecules can insert and perturb their activity. Thus, the development of technologies for the targeted intracellular delivery of antibodies, their fragments, or antibody-like molecules is extremely important. Various strategies for intracellular targeting of antibodies via protein-transduction domains or their mimics, liposomes, polymer vesicles, and viral envelopes, are reviewed in this article. The pitfalls, challenges, and perspectives of these technologies are discussed.
format Online
Article
Text
id pubmed-6207587
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62075872018-11-07 Targeted Intracellular Delivery of Antibodies: The State of the Art Slastnikova, Tatiana A. Ulasov, A. V. Rosenkranz, A. A. Sobolev, A. S. Front Pharmacol Pharmacology A dominant area of antibody research is the extension of the use of this mighty experimental and therapeutic tool for the specific detection of molecules for diagnostics, visualization, and activity blocking. Despite the ability to raise antibodies against different proteins, numerous applications of antibodies in basic research fields, clinical practice, and biotechnology are restricted to permeabilized cells or extracellular antigens, such as membrane or secreted proteins. With the exception of small groups of autoantibodies, natural antibodies to intracellular targets cannot be used within living cells. This excludes the scope of a major class of intracellular targets, including some infamous cancer-associated molecules. Some of these targets are still not druggable via small molecules because of large flat contact areas and the absence of deep hydrophobic pockets in which small molecules can insert and perturb their activity. Thus, the development of technologies for the targeted intracellular delivery of antibodies, their fragments, or antibody-like molecules is extremely important. Various strategies for intracellular targeting of antibodies via protein-transduction domains or their mimics, liposomes, polymer vesicles, and viral envelopes, are reviewed in this article. The pitfalls, challenges, and perspectives of these technologies are discussed. Frontiers Media S.A. 2018-10-24 /pmc/articles/PMC6207587/ /pubmed/30405420 http://dx.doi.org/10.3389/fphar.2018.01208 Text en Copyright © 2018 Slastnikova, Ulasov, Rosenkranz and Sobolev. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Slastnikova, Tatiana A.
Ulasov, A. V.
Rosenkranz, A. A.
Sobolev, A. S.
Targeted Intracellular Delivery of Antibodies: The State of the Art
title Targeted Intracellular Delivery of Antibodies: The State of the Art
title_full Targeted Intracellular Delivery of Antibodies: The State of the Art
title_fullStr Targeted Intracellular Delivery of Antibodies: The State of the Art
title_full_unstemmed Targeted Intracellular Delivery of Antibodies: The State of the Art
title_short Targeted Intracellular Delivery of Antibodies: The State of the Art
title_sort targeted intracellular delivery of antibodies: the state of the art
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207587/
https://www.ncbi.nlm.nih.gov/pubmed/30405420
http://dx.doi.org/10.3389/fphar.2018.01208
work_keys_str_mv AT slastnikovatatianaa targetedintracellulardeliveryofantibodiesthestateoftheart
AT ulasovav targetedintracellulardeliveryofantibodiesthestateoftheart
AT rosenkranzaa targetedintracellulardeliveryofantibodiesthestateoftheart
AT sobolevas targetedintracellulardeliveryofantibodiesthestateoftheart